These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24359775)

  • 1. Tyrosine kinase inhibitory activity of dehydroabietylamine derivatives tested by homogeneous time-resolved fluorescence based high throughput screening model.
    Zhou TT; He L; Yan M; Zhang LY; He JG; Rao XP
    Chin J Nat Med; 2013 Sep; 11(5):506-13. PubMed ID: 24359775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors].
    Li XG; Wang GF; Zhang JY; Wu SY; Xu W; Wu SG; Zhang JJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Aug; 29(8):1612-4. PubMed ID: 19726307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HTRF Kinase Assay Development and Methods in Inhibitor Characterization.
    Jia Y; Manuia M; Juarez J
    Methods Mol Biol; 2016; 1360():1-18. PubMed ID: 26501898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening enzyme-inhibitory activity in several ascidian species from Orkney Islands using protein tyrosine kinase (PTK) bioassay-guided fractionation.
    Barenbrock JS; Köck M
    J Biotechnol; 2005 May; 117(3):225-32. PubMed ID: 15862352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening.
    Lin LG; Xie H; Li HL; Tong LJ; Tang CP; Ke CQ; Liu QF; Lin LP; Geng MY; Jiang H; Zhao WM; Ding J; Ye Y
    J Med Chem; 2008 Aug; 51(15):4419-29. PubMed ID: 18610999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKbeta-NEMO interaction.
    Gotoh Y; Nagata H; Kase H; Shimonishi M; Ido M
    Anal Biochem; 2010 Oct; 405(1):19-27. PubMed ID: 20522330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
    Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
    Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An improved zinc cocktail-mediated fluorescence polarization-based kinase assay for high-throughput screening of kinase inhibitors.
    Chopra P; Nanda K; Chatterjee M; Bajpai M; Dastidar SG; Ray A
    Anal Biochem; 2008 Sep; 380(1):143-5. PubMed ID: 18570885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronidazole acid acyl sulfonamide: a novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors.
    Luo Y; Li Y; Qiu KM; Lu X; Fu J; Zhu HL
    Bioorg Med Chem; 2011 Oct; 19(20):6069-76. PubMed ID: 21920766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors.
    Marzaro G; Chilin A; Guiotto A; Uriarte E; Brun P; Castagliuolo I; Tonus F; González-Díaz H
    Eur J Med Chem; 2011 Jun; 46(6):2185-92. PubMed ID: 21447431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.